| | Yourgene Health (part of the Novacyt Group), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces Australian regulatory approval for its Yourgene® Insight DPYD assay. | |
|
| | New research in the November 2026 issue of JNCCN-Journal of the National Comprehensive Cancer Network found that patients with advanced non-small cell lung cancer (NSCLC) lived longer when they received broad-based genomic sequencing (BGS)-testing a large panel of dozens or hundreds of genes at once-before starting treatment, compared with patients who received more limited biomarker testing of just one or two genes. | |
|
| | For more than three decades, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center researchers have pursued an ambitious idea: that vaccines could train the immune system to recognize and fight cancer. | |
|
| | Hoag researchers announced a first in the world discovery of a molecular warning signal in the blood that identifies serous tubal intraepithelial carcinoma (STIC), an early, precancerous stage of high-grade serous ovarian cancer (HGSOC). | |
|
| | A research team has identified an enzyme that helps acute myeloid leukemia (AML) cells survive by protecting c-MYC, a protein that drives cell growth, from degradation. | |
|
| | Sometimes innovation in cancer care means developing something entirely new. Other times, it means returning to an old idea with the knowledge and tools to make it work better. | |
|
| | For years, older patients with acute myeloid leukemia-an aggressive cancer of the blood and bone marrow-have needed clinic injections five to seven days a month, plus a daily oral pill. For these older patients, that clinic schedule can be quite demanding. | |
|
| | Final results from the phase 2 PECATI clinical trial demonstrate encouraging long-term survival outcomes with the combination of lenvatinib and pembrolizumab in patients with previously treated advanced B3-thymoma and thymic carcinoma. | |
|
| | Molecular diagnostic approaches are expanding what information is available for clinicians and laboratory professionals, including uncovering antimicrobial resistance, identifying pathogens missed by conventional methods, revealing cancer recurrence risks and characterizing complex tumor biology. | |
|
| | Triple-negative breast cancer, which accounts for approximately 10–15% of all breast cancer cases, is considered particularly difficult to treat because it grows rapidly and carries a high risk of recurrence. | |
|
| | A new peer-reviewed review in Psychedelics opens on a strange fact, gathered from existing laboratory studies rather than new experiments: a brain tumor can learn to eavesdrop. | |
|
| | In a new clinical trial, researchers have interrogated how patients with an aggressive form of lung cancer respond to treatment with a triple combination therapy. | |
|
| | Researchers found that maternal exposure to polystyrene nanoplastics disrupted early ovarian development in female mouse offspring, reducing primordial follicle numbers by approximately 22%. The findings linked impaired follicle formation to altered adhesion between immature egg cells, reduced granulosa cell proliferation, and increased apoptosis, although the long-term effects on fertility and relevance to humans remain uncertain. | |
|
| | Protein patterns in melanoma tumors can predict how patients respond to immunotherapy and can be used to find promising biomarkers and drug targets, according to two new University of Pittsburgh studies. | |